SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about press release

21 Aug 2024 Evaluate
Aurobindo Pharma has informed that further to its letters dated Monday, July 22, 2024 and Thursday, August 01, 2024, whereby it submitted the public announcement dated Friday, July 19, 2024 (Public Announcement) and the letter of offer dated Thursday, August 01, 2024 (Letter of Offer) respectively, pertaining to the captioned Buyback. As required under the Buyback Regulations, it enclosed a copy of the post buyback public advertisement dated Tuesday, August 20, 2024 (Post Buyback Public Advertisement), which was published on Wednesday, August 21, 2024, in the following newspaper: Financial Express, Jansatta, and Nava Telangana.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×